Sweden's Bonesupport Q1 net sales rise 14% yr/yr on US segment growth

BoneSupport Holding AB

22/04/2026 07:12

Overview

Sweden orthobiologics maker's Q1 net sales rose 14% yr/yr

Adjusted EPS for Q1 improved to SEK 0.81 from SEK 0.16 yr/yr

US CMS proposes improved reimbursement for CERAMENT products, final decision expected late summer

Outlook

Company notes US CMS proposes improved reimbursement for CERAMENT G from 2027, decision expected late summer

Company says CMS proposes NTAP for CERAMENT V from Oct 1, 2026, pending FDA approval by Apr 30, 2026

Result Drivers

US SEGMENT GROWTH - US sales rose 16% yr/yr (35% at constant exchange rates), supported by CERAMENT G performance

EUROPE & REST OF WORLD GROWTH - Europe & Rest of the World sales increased 9% yr/yr (16% at constant exchange rates)

CLINICAL PUBLICATIONS - Company highlighted publication of US-based clinical studies on CERAMENT G for bone infection and infection prevention

Company press release: ID:nMFN9qTzCv

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
SEK 324 mln
SEK 331 mln (2 Analysts)
Q1 Adjusted EPS
SEK 0.81
Q1 Gross Margin
92.2%
Q1 EBIT
SEK 72.2 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Bonesupport Holding AB is SEK387.50, about 50.8% above its April 21 closing price of SEK257.00

The stock recently traded at 46 times the next 12-month earnings vs. a P/E of 35 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)